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Abstract 
 
Background: New methods to identify bladder cancer progression are required. Gene-
expression microarrays can reveal insights into disease biology and identify novel 
biomarkers. However, these experiments produce large datasets that are hard to interpret.  
 
Objective: To develop a novel method of microarray analysis combining two forms of 
artificial intelligence (AI): NeuroFuzzy Modeling (NFM) and Artificial Neural Networks 
(ANN). To validate this in a bladder cancer cohort. 
 
Design, Setting, and Participants: We used AI and statistical analyses to identify 
progression-related genes in a microarray dataset (n=66 tumors, n=2,800 genes). The AI-
selected genes were then investigated in a second cohort (n=262 tumors) using 
immunohistochemistry. 
 
Measurements: We compared the accuracy of AI and statistical approaches to identify 
tumor progression. 
 
Results and limitations: AI identified 11 progression-associated genes (OR=0.70 (95% 
CI=0.56-0.87) p=0.0004) and these were more discriminate than genes chosen using 
statistical analyses (OR=1.24 (95% CI=0.96-1.60) p=0.09). The expression of 6 AI-
selected genes (LIG3, Fas, KRT18, ICAM1, DSG2 and BRCA2) was determined using 
commercial antibodies and successfully identified tumor progression (Concordance 
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Index=0.66, Logrank p=0.01). AI-selected genes were more discriminate than 
pathological criteria at determining progression (Cox multivariate analysis p=0.01). 
Limitations include the use of statistical correlation to identify 200 genes for AI analysis 
and that we did not compare regression identified genes with immunohistochemistry.  
 
Conclusions: AI and statistical analyses use different techniques of inference to 
determine gene-phenotype associations and identify distinct prognostic gene signatures 
that are equally valid. We have identified a prognostic gene signature, whose members 
reflect a variety of carcinogenic pathways, which could identify progression in non-
muscle invasive bladder cancers. 
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Introduction 
The care of patients with Urothelial Carcinoma of the bladder (UCC) could be 
significantly improved if their tumor behavior was accurately identified at diagnosis. 
Patients with non-progressive superficial disease could be spared endoscopic surveillance 
and BCG immunotherapy, whilst those at high progression risk could opt for early 
cystectomy. For invasive tumors the use of systemic chemotherapy could be rationalized 
to cases with highest progression risk. Tumor behavior can be hard to determine from 
histopathology alone. For example, the progression risk for non-muscle UCC varies 
between <1% and >50% [1, 2]. Furthermore, as stage and grade are often linked, when 
one is fixed (e.g. stage) the other performs poorly (e.g. grade) at identifying tumor 
progression. It is hoped that molecular knowledge will reveal an understanding of tumor 
biology that allows accurate phenotype identification.  
 
As current biomarkers are insufficiently robust for clinical practice, microarrays have 
been used to identify new candidates [3] [4]. Microarray experiments reveal great 
insights into tumor biology but the cost and magnitude of these experiments prohibit 
large sample size analyses. Thus, microarray datasets have high dimensionality (large 
imbalance between gene number and sample size) that leads to analytical difficulties [5] 
[6] [7]. Successful analysis requires the identification of genes related to tumor-class and 
the removal of non-contributing variables. Poor analysis leads to data over-fitting and 
irreproducible results [5]. Traditional analytical techniques, such as hierarchical 
clustering, assume biological linearity and use statistical proximity to infer class-gene 
relationships (so  called  ‘feature selection’). They perform poorly in datasets 
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contaminated with variable noise. Artificial intelligence (AI) is a machine learning 
approach without these prerequisites. Various AI techniques exist [8] and successful 
microarray analysis has been reported using artificial neural networks (ANN) [9] [10] and 
support vector machines (SVMs) [11, 12] in non-urothelial malignancies. However, the 
hidden working layer of an ANN prevents model understanding and hinders its 
acceptance by the scientific community [13], whilst SVMs still use proximity to infer 
class-gene associations and function poorly with respect to interpretability [14]. 
 
An alternative form of AI is the neurofuzzy model (NFM). This has a similar design to an 
ANN, but uses a transparent fuzzy logic internal structure [8]. This transparency allows 
model understanding, parameter interrogation and can facilitate the inclusion of priori 
qualitative knowledge. When used to identify tumor progression we have previously 
found that NFM is accurate, reproducible and appears superior to regression based 
classifications [15, 16]. We hypothesized that NFM could improve microarray analysis 
and identify prognostic gene panels that could accurately predict the behavior of UCC. 
To test this hypothesis we examined a previously reported non-muscle invasive UCC 
microarray dataset to find genes associated with progression to invasion. Genes 
associated with progression were then tested in a new larger UCC cohort using 
immunohistochemistry. 
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Materials and methods 
Patients and Tumors 
We studied two patient populations (Table 1). For microarray analysis we used 66 tumors 
from 34 patients, treated at the Ludwig Maximilian University, Germany (detailed in 
[17]). Progression to muscle invasion occurred in 10/34 patients (29%) and the median 
follow up was 43 months. For immunohistochemical analysis we studied 262 tumors 
from separate consecutive patients treated at the University of Regensburg, Germany. We 
created a tissue microarray (TMA) using paraffin embedded formalin fixed tissues with 2 
cores per cases (1.2mm) [18]. Progression information was available for 182/262 (69.5%) 
patients and muscle invasion or new metastases occurred in 49 patients (26.9%). The 
median follow up was 89 months (range 2-154). No patients were in both UCC 
populations. Normal urothelium from patients with benign prostatic hyperplasia (n=20) 
and co-existing UCC (n=15) was also analyzed. Institutional review board approval was 
obtained from both institutions prior to study commencement. 
 
RNA Extraction and Gene Expression Microarray Analysis 
The microarray (metg001A) contained 2,800 genes (6,117 probesets) annotated by the 
GoldenPath assembly. The microarray experiments and data processing are reported in 
detail elsewhere [17]. 
  
Artificial Intelligence Feature Selection  
To analyze the microarray data we used a ‘Committee  of  models’  approach that 
assimilated findings from each individual AI model (Figure 1), as we wanted to 
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determine gene-progression relationships that were not dependent upon one AI structure. 
We initially performed a dimension reduction using Pearson’s coefficient to identify the 
200 genes most associated with progression. These selected genes were then analyzed 
using iterative ANN and NFM models in two structures, which we  termed  ‘Selectivity’ 
and  ‘Averaging’ (Figure 1). These structures enable simultaneous analysis of all genes, 
rather than a ‘Leave-One-Out’ approach. ANNs were produced within Statistica (Version 
7, StatSoft Ltd, Bedford, UK). NFMs were produced within Matlab (Version 6.5 
www.mathworks.com) and progression predictions performed using an in-house software 
suite [19, 20]. The data were divided into 90% for training (60% was learning and 30% 
for validation) and 10% for testing. Ensembling and cross validation were used to 
maximize data [21].  
 
We ranked the 200 genes according to the size of model error induced by their alteration. 
Those with largest error were ranked highest, as alteration of their values produced the 
largest disturbance in the models accuracy. For each gene a ‘Committee’  ranking was 
produced from the average score of the individual AI models. A panel of progression 
related genes was produced from those with the highest ranking. This Committee panel 
was compared with the ‘Original’ gene panel selected using Pearson’s linear regression 
coefficient and GeneCluster 2.0 software [17]. This Original panel included 11 members 
(FABP4, GSTM4, SERPINA1, HDAC1, C20ORF1, DNLC2A, PTK6 UBC, MGMT, 
ITGB3BP and PAIP2). 
 
Immunohistochemistry 
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To evaluate the Committee approach we analyzed the expression of its highest ranking 
members using immunohistochemistry in a new UCC cohort [17, 22]. Commercially 
manufactured antibodies were available for six members: LIG3 (clone 6G9; Abcam, 
Cambridge, UK; dilution 1:50), BRCA2 (Abcam, Cambridge, UK; dilution 1:10), 
TNFRSF6 (Abcam, Cambridge, UK; dilution 1:25), KRT18 (clone CK2; Chemicon, 
Billerica, MA, USA; dilution 1:50), DSG2 (clone 3G132; Abcam, Cambridge, UK; 
dilution 1:10), and ICAM1 (clone 23G12; Lab Vision, Fremont, CA, USA; dilution 
1:10). For negative controls the primary antibody was omitted. Immunostained sections 
were scored independently for the percentage of positive tumor cells by uropathologists 
(PW, AH). The abnormal status for each protein was defined according to its cellular 
function, its contrast with normal urothelial expression and from previous reports. For 
ICAM1, a case was considered positive if > 30% of intra-tumoral blood vessels were 
stained. For LIG3, BRCA2, TNFRSF6, and DSG2 abnormal expression was defined as a 
loss or reduction of staining (0% or ≤30%  positively  stained  cells).  For  both,  normal 
urothelium had expression in >50% of cells. Abnormal KRT18 expression was defined as 
increased  immunostaining  (≥80%  cells  with  positive  staining)  with  respect  to  normal 
samples, which were negative in 90% of cases.  
 
Statistical Analysis 
All analyses were two tailed and carried out using SPSS (version 14, SPSS Inc). 
Categorical variables were compared using the 2 test and continuous variables with a T 
test. Disease progression was defined when a non-muscle invasive tumor became 
invasive or a muscle invasive tumor developed metastases. Progression-specific survival 
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probability following tumor resection was analyzed using the Kaplan-Meier method and 
Log rank test. Patients without progression were censored when they were last reviewed 
or when they died of other causes. The concordance index was calculated as reported 
[23]. A P value of <0.05 was interpreted as statistically significant. Cox regression 
multivariate analysis was used to compare the prognostic value of the various gene panels 
with clinicopathological parameters. 
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Results 
Dimension reduction 
We aimed to produce a prognostic gene panel of around 11 members to allow comparison 
with the Original panel chosen by statistical methods. Analysis of predictive ANN and 
NFM models with increments of 1 to 200 members revealed this was feasible (Figure 2). 
For NFM, the modeling error with 11 genes (RMS=0.135) was similar to that for more 
than 157 genes (both concordance index=1.0). For ANN the error did not change until 
more than 140 gene inputs were used (RMS = 0.37 for 11 genes), and was larger than the 
equivalent for NFM. 
  
Gene Ranking and Comparison of Feature Selection Panels 
We ranked the 200 genes according to their average score from the various AI models 
(Table 2) and selected the 11 highest ranked genes to compare with the Original panel. 
Using gene expression, dichotomized around the mean, both panels were able to stratify 
tumor progression, although the Committee panel appeared more discriminate. For 
example, the findings of the Committee panel are typical (Figure 3a): whilst individual 
members are associated with tumor progression (e.g. LIG3 p=0.01, KRT18 p=0.04, Log 
rank values), the best prediction of progression occurs when the members are used in 
combination (≥3/11 abnormal genes p=0.007, ≥4/11 p=0.0004, ≥5/11 p=0.002, Log rank 
values). In multivariate analysis the Committee panel (OR=0.70 (95% CI 0.56-0.87), 
Logrank p=0.0004) was better at identifying progression than grade (OR=0.38 (95% CI 
0.15-0.91, p=0.001) and stage (OR=0.65 (95% CI 0.1-4.31), p=0.03), and the Original 
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panel (OR=1.24 (95% CI 0.96-1.60), p=0.09). No members were shared between the 
Committee and Original panels. 
 
Analysis of the Committee panel in a second tumor cohort 
Six of the 11 members in the Committee panel (LIG3, BRCA2, TNFRSF6, KRT18, 
DSG2 and ICAM1, Figure 4a) have commercially manufactured antibodies with proven 
reproducible staining patterns in formalin fixed paraffin embedded tissue. Using these 
antibodies we performed immunohistochemistry on the 262 tumor TMA. When protein 
expression was analyzed with respect to tumor histology, various associations were seen. 
For example, LIG3 and ICAM1 were associated with tumor stage and grade (χ2 p<0.05) 
(Table 3), when compared to tumors with normal expression. However, when expression 
of individual proteins with respect to tumor behavior was analyzed, few significant 
relationships were present. Only abnormal TNFRSF6 expression was significantly 
associated with tumor progression (Log rank p=0.003).  
 
We then analyzed the 6 proteins together as a Committee panel using only superficial 
tumors (n=134). Each tumor was scored according to the number of proteins with 
abnormal staining and this was expressed as a percentage of the total number successfully 
immunostained for that sample. Only samples with ≥4 stained proteins were  evaluated. 
When progression was analyzed with respect to this score, significantly worse outcomes 
were present in tumors with higher than lower scores (Figure 4b). As with its use in the 
first tumor cohort, the panel’s discriminating ability was maximal at its mean content 
(Concordance index =0.66, Log rank p=0.02 for 40% and p=0.01 for 50%). In 
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multivariate analysis, the Committee panel was better at stratifying progression (Cox 
OR=1.2 (95% CI 1.1-1.3), p=0.014) than tumor stage (OR=1.44 (95% CI 0.82-2.53), 
p=0.2), grade (OR=0.93 (95% CI 0.53-1.66), p=0.8), the presence of CIS (OR=1.3 (95% 
CI 0.54-3.12), p=0.6), growth pattern (OR=0.74 (95% CI 0.26-2.12), p=0.6) and 
multifocality (OR=1.61 (95% CI 0.61-4.24), p=0.3).  
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Discussion 
Here we have used AI to examine the relationship between gene expression and 
progression. To evaluate this approach, rather than specific model designs, we used a 
Committee of models to merge gene rankings from individual models and structures. AI 
can identify complex relationships within non-linear data contaminated by variable noise 
and as such, can outperform statistical regression [8, 24]. AI modeling is a generic 
process and these methods could be applied to re-interrogate microarray datasets for 
prognostic and functional data.  
 
Our approach reduced 200 genes to 11 with minimal deterioration in progression 
identification. The highest ranked genes appeared better at predicting tumor outcome than 
those selected using traditional analysis and pathological criteria. The fuzzy logic layer of 
our Committee NFM is shown in Figure 3b. This rule-base consists of parallel rules in 
which the fuzzy logic component can be visualized. In rule 1 (top line), high KRT18 in 
combination with low DSG2 and TNFRSF6 expression leads to rapid tumor progression 
(final box). This supports known carcinogenic functions of these genes as KRT18 is an 
oncogene and the others are tumor suppressors [25]. One can also see that the 
discriminatory effects in TP53BP2 are less apparent than for other genes (TP53BP2 was 
ranked 11th, Table 2).  
 
The ability of AI to determine non-linear relationships is demonstrated in our results. Of 
the 11 genes that comprise the Committee panel, only TNFRSF6 was individually 
associated with tumor progression. However, the cumulative use of this panel allowed 
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accurate progression discrimination (Figure 4b). The members of the Committee panel 
represent various carcinogenic pathways. Their association with progression may be 
directly through carcinogenic roles or as bystanders associated with progression. Their 
diversity in roles suggests they may function as synergistic facilitators of progression. 
Apoptosis evasion is represented by reduced expression of Fas (TNFRSF6), TP53BP2 
and ARHE. Fas is important for apoptosis induction and decreased expression is 
associated with advanced bladder cancer stage, grade and progression [26]. TP53BP2 
(also ‘Apoptosis  stimulating  protein  of  p53  2’  (ASPP2))  plays a key role in apoptosis 
induction through the activation of p53. Reduced TP53BP2 expression abrogates the 
onset of apoptosis in cancer, but has not been reported in UCC. Tumor invasion is 
represented by reduced cellular adhesion (ICAM1 and DSG2) and cytoskeletal re-
organization through increased KRT18 and reduced ARHE expression. DSG2 is a 
cellular adhesion molecule whose loss reduces adhesion, increases invasion and speeds 
tumor progression [27]. ICAM1 is also an intercellular adhesion molecule and is 
frequently epigenetically silenced in UCC (>70%) [28]. KRT18 is a cytokeratin known to 
be expressed in the umbrella layer of urothelium whose expression increases with 
urothelial carcinogenesis [25]. ARHE  (also  ‘Rho  family GTPase  3’  (RND3))  is  a Rho 
signal transduction member with roles in many cellular processes (cytoskeleton 
organization, membrane trafficking, cell growth and apoptosis) [29], whose loss is 
reported in prostate cancer. Deranged DNA repair is represented by BRCA2 and LIG3 
[30].Whilst neither is directly linked with bladder carcinogenesis, it is possible that loss 
of both is required for carcinogenic alteration. BRCA2-deficient cells have reduced DNA 
ligation capacity which can be reversed by LIG3 administration [30]. 
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Conclusion 
AI can analyze microarray datasets in a complementary manner to statistical analyses. 
Both methods use different techniques of inference to determine gene-phenotype 
associations and thus identify distinct prognostic gene signatures that are equally valid. 
We have identified a new prognostic gene signature in UCC, whose members reflect a 
variety of carcinogenic pathways. This signature requires validation in new tumor cohorts 
to assess its ability to identify progression in non-muscle invasive bladder cancers. 
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F igure Legends 
 
Fig. 1. The Work flow for this report. Pearson coefficient was used to reduce the 2,800 
genes to the 200 most associated with progression. These genes were modelled by 
separate ANNs and NFMs. For each model 200 iterations were run. Each iteration 
studied a single gene and consisted of training/validation/testing of the model. The 
model’s error was the score that determined the significance of the gene being tested in 
that iteration. In the Selectivity approach, we changed all 200 gene values to their mean 
and then individually maximized (largest value seen) and minimized single genes. 
Following model testing the analysed gene was returned to average before starting the 
next iteration. This approach hoped to find genes whose extreme presence caused most 
disruption to the model. In the Averaging approach, all 200 genes were left unchanged 
whilst single individual genes were averaged for their model iteration. This model aimed 
to find those genes whose loss of profile resulted in most disruption to the model. Gene 
rankings from these models were then averaged to generate the Committee of models 
ranking. The highest ranking members were then compared with the Original panel 
identified by Wild et al [17] by predicting progression in the same UCC cohort. Six 
members had commercial antibodies and their expression was tested in a new cohort of 
UCC. 
 
Fig. 2. Performance of the AI models during dimension reduction. (a). The model error 
for 1-200 genes is shown (RMS value). In general, NFM has a lower error than ANN. A 
panel with 11 genes has a similar error to that with 158 genes (NFM) or 140 genes 
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(ANN). (b) Correct progression classifications (percentage) with NFM or ANN using 
models with n1-200 genes. 
 
Fig. 3. The Committee panel for Superficial UCC progression prediction. (a). Tumour 
progression stratified by pathological grade, the Original and Committee panels. (b). 
NFM rule base for the Committee panel. Probe values are coloured according to value 
around mean (reduced = red, increased = blue and mean = black).  
 
Fig. 4. Tumor progression using immunohistochemistry for members of the Committee 
panel. (a) Abnormal expression of panel members in UCC (Insert boxes show expression 
in normal urothelium: strong membranous TNFRSF6 staining; KRT18 confined to 
umbrella cells; strong nuclear LIG3 and BRCA2 staining; weak membranous DSG2 
staining; very weak ICAM1 staining of urothelium and strong staining within the 
endothelium of capillaries). (b). Tumor progression stratified by grade and the Committee 
panel in the second superficial UCC population (n=134). A bad signature is defined as 
≥50% proteins with abnormal expression. 
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 Table 1. The two UCC cohorts studied in this report  
 
    i. Gene array tumors ii. TMA tumors 
    n % n % 
Gender Male 29 85.3% 194 73.8% 
 Female 5 14.7% 68 25.9% 
Stage TNM 1998 Normal 8 100.0%   
 pTis 3 4.5%   
 pTa 46 69.7% 149 56.7% 
 pT1 10 15.2% 49 18.6% 
 pT2 7 10.6% 59 22.4% 
 pT3   2 0.8% 
 pT4   3 1.1% 
Stage TNM 2004 PUNLMP 1 1.5% 22 8.4% 
 pTis 3 4.5%   
 pTa 45 68.2% 127 48.3% 
 pT1 10 15.2% 49 18.6% 
 pT2 7 10.6% 59 22.4% 
 pT3   2 0.8% 
 pT4   3 1.1% 
Grade Grade 1 27 40.9% 83 31.6% 
 Grade 2 24 36.4% 69 26.2% 
 Grade 3 15 22.7% 110 41.8% 
Growth pattern Papillary 55 83.3% 210 79.8% 
 Solid 11 16.7% 51 19.4% 
 Unknown   1 0.4% 
Multiplicity Unifocal 29 43.9% 54 20.5% 
 Multifocal 37 56.1% 208 79.1% 
Carcinoma in situ No pTis 62 93.9% 227 86.3% 
 pTis 4 6.1% 35 13.3% 
Tumor Metastasis   2 0.8% 
 Primary UCC 25 37.9% 255 97.0% 
 Recurrent UCC 41 62.1% 5 1.9% 
Progression rate 10/34* 29.4% 36/134*** 26.9% 
Median (range) time to progression 21 (0-60) months 23 (1-154) months 
Overall survival unknown  167/198 84.3% 
Median (range) overall survival time** 43 (0-109) months 90 (24-154) months 
  Total UCC 66 100.0% 262 100.0% 
* in the 34 individual patients     
** in non-progressing patients 
*** in 134 primary superficial tumors with available follow up information 
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